drug_type
RELEVANT_DRUG
intervention_type
biologic (antibody-photoabsorber conjugate; photoimmunotherapy)
drug_description
Antibody-photoabsorber conjugate targeting EGFR. After intravenous dosing, tumor sites are illuminated at 690 nm to activate the IR700 dye, causing selective tumor cell membrane damage and immunogenic cell death (photoimmunotherapy).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
EGFR-targeted antibody–photoabsorber conjugate (cetuximab linked to IR700). After IV administration and binding to EGFR+ tumor cells, localized 690 nm light activates IR700, causing rapid, selective tumor cell membrane disruption and immunogenic cell death (photoimmunotherapy), enhancing antitumor immune responses.
drug_name
ASP-1929 (cetuximab sarotalocan)
nct_id_drug_ref
NCT06699212